Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.
作者信息
Miao Yi, Sha Yeqin, Xia Yi, Qin Shuchao, Jiang Rui, Dai Luomengjia, Shen Hui, Qiu Tonglu, Wu Wei, Qiu Jingyan, Yang Yilian, Ding Chongyang, Wu Yujie, Fan Lei, Xu Wei, Li Jianyong, Zhu Huayuan
机构信息
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
Pukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China.
出版信息
Blood Cancer J. 2023 Aug 9;13(1):121. doi: 10.1038/s41408-023-00890-y.
Abstract
摘要
Zotero 插件